SCHEMBL7236604

SCHEMBL7236604

Cc1ccc(-c2cc(C(=O)N3CCC[C@H]3CO)c3ccccc3n2)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 1/20 0.48
RAB9A P51151 1/20 0.46
KDM4E B2RXH2 6/20 0.46
MAPK1 P28482 3/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TRPV1 Q8NER1 1/20 0.44
ALDH1A1 P00352 2/20 0.43
USP2 O75604 1/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RAD52 P43351 1/20 0.43
HCRTR1 O43613 3/20 0.43
HCRTR2 O43614 3/20 0.43
ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7236610 1.00 POLB (0.48) POLBKMT2AMEN1RAB9AKDM4E
SCHEMBL6163609 0.91 HCRTR1 (0.51) POLBKMT2AMEN1RAB9AKDM4E
SCHEMBL6165786 0.91 HCRTR1 (0.51) POLBKMT2AMEN1RAB9AKDM4E
SCHEMBL6165793 0.91 HCRTR1 (0.51) POLBKMT2AMEN1RAB9AKDM4E
SCHEMBL6165649 0.90 TRPV1 (0.44) POLBKMT2AMEN1RAB9AKDM4E
SCHEMBL6166196 0.90 TRPV1 (0.44) POLBKMT2AMEN1RAB9AKDM4E
SCHEMBL6167460 0.90 TRPV1 (0.44) POLBKMT2AMEN1RAB9AKDM4E
SCHEMBL6164237 0.90 MEN1 (0.49) POLBKMT2AMEN1RAB9AKDM4E
SCHEMBL6163315 0.90 MEN1 (0.49) POLBKMT2AMEN1RAB9AKDM4E
SCHEMBL6165671 0.90 MEN1 (0.49) POLBKMT2AMEN1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US disclosed